HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 41, 2013, Pages 16538-16543

  Horwitz, Joshua A ^a   Halper Stromberg, Ariel ^a   Mouquet, Hugo ^a,b   Gitlin, Alexander D ^a   Tretiakova, Anna ^c   Eisenreich, Thomas R ^a   Malbec, Marine ^d   Gravemann, Sophia ^e   Billerbeck, Eva ^f   Dorner, Marcus ^f   Büning, Hildegard ^e   Schwartz, Olivier ^d   Knops, Elena ^e   Kaiser, Rolf ^e   Seaman, Michael S ^g   Wilson, James M ^c   Rice, Charles M ^f   Ploss, Alexander ^f,g   Bjorkman, Pamela J ^h,i   Klein, Florian ^a   Nussenzweig, Michel C ^a,j   more..

^a Building 10   (United States)

^b Department of Immunology   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INSTITUT PASTEUR   (France)

^e Laboratory of Virology and Infectious Disease   (United States)

^f Division of Biology   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h PRINCETON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j ROCKEFELLER UNIVERSITY   (United States)

more..

Author keywords

CD4bs; Glycan; Gp160

Indexed keywords

ANTIRETROVIRUS AGENT; NEUTRALIZING ANTIBODY; VIRUS DNA;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOTHERAPY; INJECTION; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

CD4BS; GLYCAN; GP160;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIBODIES, NEUTRALIZING; DEPENDOVIRUS; DNA PRIMERS; DNA, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 84885338257     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1315295110     Document Type: Article

References (50)

1. Molina J-M, et al.; CASTLE Study Team (2010) Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 53(3):323-332.
2. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F (2001) Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 15(11):1369-1377.
3. Arts EJ, Hazuda DJ (2012) HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2(4):a007161.
4. Hamlyn E, et al.; INSIGHT SMART and SPARTAC Investigators (2012) Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS ONE 7(8):e43754.
5. Sigal A, et al. (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477(7362):95-98.
6. Eisele E, Siliciano RF (2012) Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37(3):377-388.
7. Deeks SG, et al.; International AIDS Society Scientific Working Group on HIV Cure (2012) Towards an HIV cure: A global scientific strategy. Nat Rev Immunol 12(8): 607-614.
8. Mascola JR, et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73(5):4009-4018.
9. Shibata R, et al. (1999) Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5(2):204-210.
10. Moldt B, et al. (2012) Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 109(46):18921-18925.
11. Poignard P, et al. (1999) Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10(4):431-438.
12. Trkola A, et al. (2005) Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11(6):615-622.
13. Mehandru S, et al. (2007) Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 81(20):11016-11031.
14. Scheid JF, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458(7238):636-640.
15. McCoy LE, Weiss RA (2013) Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 210(2):209-223.
16. Moir S, Malaspina A, Fauci AS (2011) Prospects for an HIV vaccine: Leading B cells down the right path. Nat Struct Mol Biol 18(12):1317-1321.
17. Diskin R, et al. (2011) Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334(6060):1289-1293.
18. Walker LM, et al.; Protocol G Principal Investigators (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477(7365):466-470.
19. Mouquet H, et al. (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA 109(47):E3268-E3277.
20. Wu X, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329(5993):856-861.
21. Scheid JF, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333(6049):1633-1637.
22. Walker LM, et al.; Protocol G Principal Investigators (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326(5950):285-289.
23. Klein F, et al. (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492(7427):118-122.
24. Diskin R, et al. (2013) Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J Exp Med 210(6):1235-1249.
25. Simek MD, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a highthroughput neutralization assay together with an analytical selection algorithm. J Virol 83(14):7337-7348.
26. Gray ES, et al.; CAPRISA002 Study Team (2011) The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 85(10):4828-4840.
27. Liao HX, et al.; NISC Comparative Sequencing Program (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496(7446):469-476.
28. Wu X, et al.; NISC Comparative Sequencing Program (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333(6049): 1593-1602.
29. Mouquet H, et al. (2011) Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS ONE 6(9):e24078.
30. Burton DR, et al. (2012) A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 12(4):396-407.
31. McLellan JS, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480(7377):336-343.
32. Baenziger S, et al. (2006) Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/-mice. Proc Natl Acad Sci USA 103(43): 15951-15956.
33. Goujard C, et al. (2006) CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 42(5):709-715.
34. Pasternak AO, Lukashov VV, Berkhout B (2013) Cell-associated HIV RNA: A dynamic biomarker of viral persistence. Retrovirology 10:41.
35. García F, et al. (1999) Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13(11):F79-F86.
36. Harrigan PR, Whaley M, Montaner JS (1999) Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13(8):F59-F62.
37. Nischang M, et al. (2012) Humanized mice recapitulate key features of HIV-1 infection: A novel concept using long-acting anti-retroviral drugs for treating HIV-1. PLoS ONE 7(6):e38853.
38. Balazs AB, et al. (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481(7379):81-84.
39. Johnson PR, et al. (2009) Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15(8):901-906.
40. Mascola JR, Montefiori DC (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28:413-444.
41. Overbaugh J, Morris L (2012) The antibody response against HIV-1. Cold Spring Harb Perspect Med 2(1):a007039.
42. Abela IA, et al. (2012) Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 8(4):e1002634.
43. Zhang MY, et al. (2010) Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. MAbs 2(3):266-274.
44. Martin N, et al. (2010) Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition.J Virol 84(7):3516-3527.
45. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O (2007) Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 81(2):1000-1012.
46. Girard MP, Picot V, Longuet C, Nabel GJ (2013) Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV. Part 1: Broadly neutralizing antibodies. Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012. Vaccine 31(29):2979-2983.
47. Denton PW, et al. (2012) Generation of HIV latency in humanized BLT mice. J Virol 86(1):630-634.
48. Choudhary SK, et al. (2009) Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-gammac-/-mouse. J Virol 83(16):8254-8258.
49. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22(3):659-661.
50. Wang L, et al. (2010) Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol Ther 18(1):118-125.